Nanologica has recruited Katarina Alenäs as VP Chromatography to lead Nanologica's sales organization within Chromatography globally.
As sales start for preparative chromatography approaches, Nanologica's sales organization is now strengthened with Katarina Alenäs as VP Chromatography. The assignment includes leading the sales organization and driving the work globally. Nanologica thus has its own sales organization covering all major markets – India, China, US and Europe.
" With solid experience from the biotechnology industry in general and the chromatography industry in particular, Katarina is utterly suited to assume the role of global sales manager for our chromatography business. In the situation the company is now, with sales start moving ever closer, Katarina is a very welcome addition to the organization. With her expertise and drive, we are taking a further step towards building a world-class chromatography sales organization and it puts us in a position to accelerate our venture in preparative chromatography," says Andreas Bhagwani, CEO of Nanologica.
Katarina comes most recently from the role as Business Team Manager Instruments Sweden & Finland and Country General Manager Sweden at Agilent Technologies, where she has been ultimately responsible for Agilent Technologies' operations in Sweden, as well as responsible for sales of instruments for chromatography, mass spectrometry and spectroscopy in Sweden and Finland.
Katarina has previously been Product Manager Shimadzu HPLC/LCMS and has worked as a product and method developer for Kromasil's silica-based packing media for preparative chromatography. Katarina’s appointment will be effective April 1 at the latest.
For further information, please contact:
Johanna Johansson, IR Manager
Ph: +46 72 211 21 90 or e-mail: email@example.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility for innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Drug Development, Nanologica provides a unique drug delivery platform for local delivery of drugs to the lung with the aim of providing new treatment options for patients with lung diseases. In Chromatography, the company aims to make insulin available to more patients in need, by lowering the cost of manufacturing. Nanologica is headquartered in Södertälje and the company’s share (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.
This information in this press release is information Nanologica AB is obliged to make public pursuant to the Market Abuse Regulation issued by the EU. The information was submitted for publication through the agency of the contact person above on December 6, 2021.